APAC CRO MARKET
Get instant access to latest e-book

latest newsRead more...

19

Jan 2019

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies

Obsidian Therapeutics a biotechnology company developing cell therapies with pharmacologic operating systems today announced a strategic collaboration with Celgene Corporation NASDAQ CELG for the discovery and development of novel regulated cell therapies that utilize Obsidians Destabilizing Domain DD technology Specifically the collaboration is based on…

19

Jan 2019

Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

Kyn Therapeutics a clinicalstage biotechnology company advancing research into new immunometabolic therapies for treating cancer today announced it has entered into a global strategic collaboration with Celgene Corporation The goal of the collaboration is to develop novel immunooncology therapies through uniting Kyns immunooncology expertise and…

18

Jan 2019

AMAG Pharmaceuticals Completes Acquisition of Perosphere Pharmaceuticals

AMAG Pharmaceuticals Inc announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc a private biopharmaceutical company Through this acquisition AMAG adds ciraparantag to its development portfolio Ciraparantag is in development as a single dose readytouse solution for use in patients…

18

Jan 2019

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

Ablexis LLC a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery today announced the expansion of its existing nonexclusive perpetual license agreement with Eli Lilly and Company The expanded rights will more broadly enable EIi Lilly to use the…

17

Jan 2019

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

Phoenix Molecular Designs a privatelyheld biotechnology company designing precise cancer therapeutics by targeting essential kinases announced that it has entered into a collaboration with Roche to develop a diagnostic CDx in triplenegative breast cancer TNBC The Roche CDx identifies RSK activation in human tumors In…

press releasesRead more...

19

Jan 2019

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

AbbVie a researchbased global biopharmaceutical company today announced an update on the Phase RESOLVE trial PCYC of ibrutinib IMBRUVICA in combination with chemotherapy agents nabpaclitaxel and gemcitabine versus placebo in…

18

Jan 2019

Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacities

Boehringer Ingelheim announced today that it has initiated a capacity expansion at its commercial manufacturing site for biologics in China The expansion covers an additional bioreactor and includes all needed…

18

Jan 2019

Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

Promentis Pharmaceuticals Inc a privatelyheld biopharmaceutical company developing innovative therapies for neuropsychiatric disorders today announced it has initiated dosing in a Phase study for its lead compound SXC for the…

17

Jan 2019

BlueRock Therapeutics Establishes Key Partnerships with Leading Experts in Autoimmune Disease

BlueRock Therapeutics LP an engineered cell therapy company leveraging its novel CellGene platform to develop regenerative medicines for intractable diseases today announced the establishment of partnerships with Bruce Blazar MD…

17

Jan 2019

Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome

Therachon AG Therachon a clinicalstage biotechnology company focused on the discovery development and commercialization of innovative treatments for serious rare conditions today announced that the US Food and Drug Administration…

EventsRead more...

21-22

Jan 2019

Pharmaceutical Microbiology UK

SMI GROUP
London, United Kingdom

21-22

Jan 2019

Social Media in the Pharmaceutical Industry

SMI Group
Holiday Inn London - Kensington Forum

21-22

Jan 2019

Pharmaceutical Microbiology

SMI Group
Copthorne Tara Hotel

22-23

Jan 2019

14th Biosimilars Summit

CBI
The Hilton Alexandria Old Town

TOP ARTICLES

  • 4

    Are you Ready for EU FMD?

    With the deadline looming for enactment of EU FMD and US DSCSA Vikash Pushpraj Senior Vice President rfxcel explains how achieving compliance is about much more..
  • 6

    Cancer Stem Cell (CSC) Inhibitors

    Cancer as a group of heterogeneous diseases very well known Unimaginable amounts of money and manhours have been spent in finding cure for this deadly disease H..

Knowledge Bank

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia
    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot..

  • Articles

    MicroRNA (miRNA) in Nanostructure Lipid Carriers based Tumor Gene Therapy

    Introduction MicroRNAs is a noncoded double stranded RNAs made of approximately of nucleotides disclosed in by Ambros and Ruvkun laboratories that has significant role in regulation of gene expression at post transcriptional level It has been identified that the noncoding region of mRNA is capable of providing targeting signals in RNA binding protein domain…

  • Techno Trends

    NRX-101 Represents New Class of Antidepressants to Decrease Suicidal Thoughts

    NeuroRxs NRX the first oral drug targeting suicidal bipolar depression helps to treat severe bipolar depression with Acute Suicidal Ideation Behavior ASIB NRX is used for treatment of Severe Bipolar Depression with Acute Suicidal Ideation Behaviour after initial stabilisation with ketamine or other effective therapy NRX Dcycloserinelurasidone fixed dose combination is the first oral drug demonstrated in human volunteers to…

Editorial Section

  • Strategy

    Statin Drug Interactions and Related Adverse Reactions

    Statins are generally well tolerated with a low frequency of adverse events but since statins are prescribed on a longterm basis many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment and potentially interacting…

  • Research development

    Stem Cell and Gene Delivery

    These days gene and stem cell therapies have the potential to make the substantial impact on the treatment of several diseases However there are pros and cons of each strategy but the optimal selection of gene delivery vector or stem…

  • Clinical Trials

    ManagingClinical TrialAgreements

    Clinical Trial Agreements set out how a clinical trial will be run at the site and are an essential GCP document There are a number of key factors that determine whether a Clinical Trial Agreement is successful in achieving that…

  • Information Technology

    R&D DATA HUB

    Faster decision making and better trial oversight at all levels requires truly next generation data integration and analytics Source and format agnostic data aggregation aided by modern data lake architecture and advanced analytics deliver interactive…

TOP